Jefferies Reiterates Buy Rating on Verastem, Inc. (VSTM)
Jefferies maintains its optimistic view on Verastem, Inc. with a buy rating and an $8.00 price target, a 131.88% upside from the current price.
Key Points
- Jefferies reiterated its buy rating on Verastem, Inc. (VSTM) with a target price of $8.00.
- Jefferies's $8 price target implies 131.88% upside from Verastem, Inc.'s ($VSTM) current $3.45 share price.
- Shares of Verastem traded near $4.25 on Tuesday, with a market cap of about $373 million.
- Insider buying was noted in May, and analysts have set optimistic price targets for the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jefferies has reiterated its buy rating for Verastem, Inc. (NasdaqCM: VSTM) with a price target of $8.00. This announcement came on June 23, 2026, as shares traded around $4.25 on Tuesday.
Jefferies vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Verastem, Inc.
Several institutional investors have made significant moves in Verastem recently. BlackRock, Inc. increased its holdings by 1,442,083 shares, bringing its total to 6,194,925 shares worth about $32.8 million, marking a 30.3% increase. Armistice Capital, LLC also boosted its stake by 1,056,000 shares to a total of 4,592,000 shares valued at $24.3 million, a 29.9% increase. Meanwhile, Nantahala Capital Management, LLC made a substantial addition, increasing its holdings by 3,122,680 shares to 3,584,820 shares, a staggering 675.7% rise, with a value of approximately $19.0 million.
Verastem, Inc. Stock Down 52.2%
Shares of Verastem, Inc. were trading near $4.25 on Tuesday. The company, with a market cap of around $373 million, operates in the biotechnology sector. It has a beta of 0.267, indicating it is less volatile than the market. The stock has seen a 52-week low of $3.55 and a high of $11.25, with moving averages of $4.90 over 50 days and $7.04 over 200 days. Verastem's financial health includes a current ratio of 3.035 and a quick ratio of 2.874, though it carries a high debt-to-equity ratio of 104.522.
$VSTM price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Verastem reported revenue of about $49.6 million, though it is not currently profitable, which is reflected in its negative return on equity of -7.86%. The company's next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Verastem, Inc.
In May 2026, several insiders, including Michael Bailey, Karin Anna Tollefson, Anil Kapur, Eric Rowinsky, Brian Stuglik, and John Johnson, each purchased 36,000 shares. These transactions were not part of planned trading programs and indicate insider confidence in the company's prospects.
Analysts Set New Price Targets
On June 23, 2026, Jefferies maintained its buy rating for Verastem with an $8.00 price target. This follows a series of bullish analyst opinions, including Mizuho and BTIG, both maintaining buy ratings with price targets of $14.00 and $18.00, respectively. The consensus among analysts is a strong buy, with an average price target of $16.00 based on 8 opinions.
About Verastem, Inc.
Verastem, Inc., headquartered in Needham, Massachusetts, is a biopharmaceutical company focused on developing cancer treatments. It is working on drugs like Avutometinib and Defactinib, aimed at tackling challenging cancer pathways. Led by CEO Daniel W. Paterson, the company employs 102 people and collaborates with major pharmaceutical firms like Pfizer and Amgen to advance its clinical programs.
Bottom Line
Jefferies' reaffirmation of its buy rating on Verastem, Inc. signals continued confidence in the company's potential to grow. Investors often watch analyst ratings closely as they provide insights into a company's future performance. However, it's important to remember that these ratings are based on past and current data, and the actual stock performance can vary.
Get Verastem, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VSTM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.